原发性醛固酮增多症诊断治疗的专家共识(2024版)  

Expert consensus on the diagnosis and treatment of primary aldosteronism(2024)

作　　者：中华医学会内分泌学分会 王卫庆[2] Chinese Society of Endocrinology;Wang Weiqing(不详;National Clinical Research Center for Metabolie Disases,Department of Endoecrine and Metabolie Diseases,Ruin Hospital,Shanghai Jiao Tong Uniuersity School of Medicine,Shanghai Institute of Endocrine and Metabolic Diseases,Shanghai 200025,China)

机构地区：[1]不详 [2]国家代谢性疾病临床医学研究中心,上海交通大学医学院附属瑞金医院内分泌代谢病科,上海市内分泌代谢病研究所,200025

出　　处：《中华内分泌代谢杂志》2025年第1期12-24,共13页Chinese Journal of Endocrinology and Metabolism

基　　金：国家科技部重点研发计划(2021YFC2501600)。

摘　　要：原发性醛固酮增多症(原醛症)是最常见的继发性高血压, 与原发性高血压患者相比, 心脑肾等靶器官受损更为严重, 为规范原醛症的诊断和治疗, 专家组在2020版共识基础上进行更新和修改。Primary aldosteronism(PA)is the most common form of secondary hypertension,characterized by more pronounced damage to target organs,including the heart,brain,and kidneys,compared to essential hypertension.To enhance the standardization of PA diagnosis and treatment,an expert panel has comprehensively updated and refined the 2020 consensus.

关 键 词：原发性醛固酮增多症 诊断 治疗 共识 

分 类 号：R586.24[医药卫生—内分泌]